OTC Markets OTCPK - Delayed Quote USD

MediPal Holdings Corporation (MEPDF)

21.06

+3.49

+(19.86%)

As of June 5 at 8:00:00 PM EDT. Market Open.

Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA

TOKYO & HYOGO, Japan, May 07, 2025--MEDIPAL and JCR announced that the U.S. FDA granted orphan drug designation (ODD) to JR-446, an investigational drug for the treatment of MPS IIIB.

Business Wire last month

JCRRF

MAHLY

MEPDF
+19.86%
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Announce Initiation of First Dosing in Phase I/II Clinical Trial of JR-446 for Mucopolysaccharidosis Type IIIB in Japan

TOKYO & HYOGO, Japan, December 05, 2024--JCR and MEDIPAL announced the initiation of the Phase I/II clinical trial of JR-446 in Japan following dosing of the first individual from the trial.

Business Wire 6 months ago

JCRRF

MAHLY

MEPDF
+19.86%

Performance Overview

Return	MEPDF	Nikkei 225 (^N225)
YTD	-275.76%	-4.53%
1-Year	+38.85%	-1.54%
3-Year	+74.79%	+34.84%